• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Heron Therapeutics Inc.

    4/30/25 1:54:22 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HRTX alert in real time by email
    DEFA14A 1 hrtx_na_defa_14a_2025.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Pursuant to §240.14a-12

     

    HERON THERAPEUTICS, INC.

    (Name of Registrant as Specified in Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     


     

     

    img189152106_0.jpg

    Your Vote Counts! HERON THERAPEUTICS, INC. 100 REGENCY FOREST DRIVE, SUITE 300 CARY, NC 27518 HERON THERAPEUTICS, INC. 2025 Annual Meeting Vote by June 11, 2025 11:59 PM ET V74542-P28909 You invested in HERON THERAPEUTICS, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 12, 2025. Get informed before you vote View the Notice and Proxy Statement and Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 29, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 12, 2025 9:00 AM Eastern Time Virtually at: www.virtualshareholdermeeting.com/HRTX2025*Please check the meeting materials for any special requirements for meeting attendance.

     


     

     

    img189152106_1.jpg

    Vote at www.ProxyVote.comTHIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items Board Recommends V74543-P28909 1. To elect six director nominees to serve until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal. Nominees: 1a. Craig Collard For 1b. Sharmila Dissanaike, M.D., FACS, FCCM For 1c. Craig Johnson For 1d. Michael Kaseta For 1e. Adam Morgan For 1f. Christian Waage For 2. To ratify the appointment of Withum as our independent registered public accounting firm for the fiscal year ending December 31, 2025. For 3. To approve, on a nonbinding advisory basis, compensation paid to our Named Executive Officers for the fiscal year ended December 31, 2024. For 4. To approve, on a nonbinding advisory basis, the frequency of future advisory votes on the compensation paid to our Named Executive Officers. 1 Year 5. To transact such other business as may properly come before the Annual Meeting. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V74543-P28909

     


    Get the next $HRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HRTX

    DatePrice TargetRatingAnalyst
    6/13/2024$7.00Buy
    Rodman & Renshaw
    4/23/2024$6.00Overweight
    CapitalOne
    3/13/2024$4.00 → $5.00Buy
    Needham
    More analyst ratings

    $HRTX
    Financials

    Live finance-specific insights

    See more
    • Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

      Generated Q1 2025 Net Revenue of $38.9 millionDelivered record Q1 2025 Adjusted EBITDA of $6.2 millionReached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI® and APONVIE® patent litigations, including an agreed market entry date of June 1, 2032Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate updates. "We are off to a strong start in 2025, achieving record adjusted EBITDA for the firs

      5/6/25 7:45:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025

      CARY, N.C., April 22, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, May 6, 2025, at 8:00 a.m. ET to report first quarter 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Invest

      4/22/25 4:05:00 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates

      Achieved Q4 2024 GAAP Net Income of $3.6 millionGenerated full-year 2024 Net Revenue of $144.2 million, up 14% year-over-yearDelivered full-year 2024 adjusted EBITDA of $8.6 millionGenerated ZYNRELEF® Q4 2024 Net Revenue of $8.5 million and launched the ZYNRELEF Vial Access Needle ("VAN") in December 2024U.S. District Court ruled in favor of Heron in patent lawsuit against Fresenius Kabi USA, LLC, and upheld the validity of CINVANTI® patents which expire in 2035 CARY, N.C., Feb. 27, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 3

      2/27/25 7:45:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

      Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling

      11/22/24 4:36:11 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for APONVIE issued to HERON THERAPS INC

      Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling

      3/11/24 4:38:31 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for CINVANTI issued to HERON THERAPS INC

      Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling

      3/11/24 4:38:29 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    SEC Filings

    See more
    • SEC Form S-8 filed by Heron Therapeutics Inc.

      S-8 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)

      5/6/25 5:00:45 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Heron Therapeutics Inc.

      10-Q - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)

      5/6/25 7:45:21 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)

      5/6/25 7:45:11 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates

      Generated Q1 2025 Net Revenue of $38.9 millionDelivered record Q1 2025 Adjusted EBITDA of $6.2 millionReached settlement with Mylan Pharmaceuticals, Inc., regarding the parties' CINVANTI® and APONVIE® patent litigations, including an agreed market entry date of June 1, 2032Adjusted EBITDA guidance raised to a range of $4 - $12M for full year 2025CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2025, and highlighted recent corporate updates. "We are off to a strong start in 2025, achieving record adjusted EBITDA for the firs

      5/6/25 7:45:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations

      — Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 — CARY, N.C., May 6, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company entered into a settlement agreement with Mylan Pharmaceuticals, Inc. ("Mylan"), a Viatris Inc. company, to resolve the ongoing patent litigations between the parties in the U.S. District Court for the District of Delaware related to CINVANTI® (aprepitant) injectable emulsion and APONVIE® (aprepitant) injectable emulsion. Pursuant to the terms of the settlement agreement, the Company has granted Mylan a license under

      5/6/25 7:30:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

      CARY, N.C., April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. "I am excited to welcome Mark to Heron as our new Chief Operating Officer," said Craig Collard, Chief Executive Officer of Heron. "Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficienc

      4/28/25 6:55:00 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Operating Officer Hensley Mark Earl

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      5/7/25 12:20:50 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Development Officer Forbes William P converted options into 11,694 shares, increasing direct ownership by 11% to 122,566 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      5/2/25 8:41:15 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chief Financial Officer Duarte Ira converted options into 11,694 shares, increasing direct ownership by 9% to 136,149 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      5/2/25 8:32:09 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Forbes William P bought $27,250 worth of shares (25,000 units at $1.09), increasing direct ownership by 46% to 79,000 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      11/21/23 12:19:26 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forbes William P bought $46,995 worth of shares (50,000 units at $0.94), increasing direct ownership by 1,250% to 54,000 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      11/20/23 10:07:28 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collard Craig A bought $137,970 worth of shares (150,000 units at $0.92), increasing direct ownership by 411% to 186,496 units (SEC Form 4)

      4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)

      11/17/23 12:37:52 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer

      CARY, N.C., April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Mark Hensley as Chief Operating Officer. Mr. Hensley has more than fifteen years of experience in a variety of sales and operations positions within the pharmaceutical industry. "I am excited to welcome Mark to Heron as our new Chief Operating Officer," said Craig Collard, Chief Executive Officer of Heron. "Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth. His experience will be instrumental in ensuring we operate with efficienc

      4/28/25 6:55:00 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

      SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company, announced today the appointment of Michael Kaseta to its Board of Directors. Mr. Kaseta has an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies. Mr. Kaseta currently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases. Prior to Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Thera

      11/4/24 5:00:00 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

      SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management team enabling the next phase of growth. "Now is the right time to add substantial BD and M&A experience to the management team at Heron, and I welcome Brett to

      9/3/24 8:00:00 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Heron Therapeutics with a new price target

      Rodman & Renshaw initiated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $7.00

      6/13/24 7:14:56 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on Heron Therapeutics with a new price target

      CapitalOne initiated coverage of Heron Therapeutics with a rating of Overweight and set a new price target of $6.00

      4/23/24 6:55:56 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Heron Therapeutics with a new price target

      Needham reiterated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $5.00 from $4.00 previously

      3/13/24 7:55:22 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Heron Therapeutics Inc.

      SC 13G - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

      11/12/24 9:32:11 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Heron Therapeutics Inc. (Amendment)

      SC 13D/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

      5/31/24 11:08:56 AM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Heron Therapeutics Inc. (Amendment)

      SC 13G/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)

      2/14/24 4:37:34 PM ET
      $HRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care